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Abstract
Background: An increasing number of patients are treated with direct-acting oral anticoagulants (DOACs), but the
optimal way to reverse the anticoagulant effect is not known. Specific antidotes are not available and prothrombin
complex concentrate (PCC), activated PCC (aPCC) and recombinant factor VIIa (rFVIIa) are variously used as reversal
agents in case of a major bleeding. We aimed to determine the most effective haemostatic agent and dose to
reverse the effect of rivaroxaban in blood samples from patients taking rivaroxaban for therapeutic reasons.
Methods: Blood samples from rivaroxaban-treated patients (n = 50) were spiked with PCC, aPCC and rFVIIa at
concentrations imitating 80%, 100% and 125% of suggested therapeutic doses. The reversal effect was assessed by
thromboelastometry in whole blood and a thrombin generation assay (TGA) in platelet-poor plasma. Samples from
healthy subjects (n = 40) were included as controls.
Results: In thromboelastometry measurements, aPCC and rFVIIa had a superior effect to PCC in reversing the
rivaroxaban-induced lenghtening of clotting time (CT). aPCC was the only haemostatic agent that shortened the CT
down to below the control level. Compared to healthy controls, patients on rivaroxaban also had a prolonged lag
time and decreased peak concentration, velocity index and endogenous thrombin potential (ETP) in platelet-poor
plasma. aPCC reversed these parameters more effectively than rFVIIa and PCC. There were no differences in efficacy
between 80%, 100% and 125% doses of aPCC.
Conclusions: aPCC seems to reverse the anticoagulant effect of rivaroxaban more effectively than rFVIIa and PCC
by evaluation with thromboelastometry and TGA in vitro.
Keywords: Rivaroxaban, Reversal, Prothrombin complex concentrate, Activated prothrombin complex concentrate,
Recombinant aFVIIa
Background
The efficacy and safety of direct-acting oral anticoagulants
(DOACs), including the factor Xa inhibitor rivaroxaban,
in the prevention and treatment of thromboembolic disor-
ders have been demonstrated in a number of clinical stud-
ies [1, 2]. It is documented that the associated bleeding
risk is lower for rivaroxaban than for warfarin [3]. Spon-
taneous and trauma-induced bleeding episodes do, how-
ever, still occur in patients on DOACs [4, 5]. Large phase
3 studies have shown that the relative risk of major bleed-
ing is 1.1% for patients taking DOACs compared to 1.8%
in patients taking warfarin. Real-world data from observa-
tional studies confirm these results [6–8]. Guidelines for
treatment of major bleedings on rivaroxaban are inconsist-
ent [9, 10]. Although routines for supportive treatment,
such as fluid replacement and blood transfusions, topical
haemostatic measures and charcoal administration in case
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of recent tablet intake have been established, there is not a
consensus on how to reverse the anticoagulant effect of
rivaroxaban in case of major or life-threatening bleeding.
A generic reversal agent of factor Xa inhibitors, andexanet
alpha, has shown promising results [11], but no antidote
is yet commercially available.
Three haemostatic agents have been suggested as sur-
rogate antidotes, but the documentation on the effect
and optimal dosage is limited and divergent. Four-factor
prothrombin complex concentrate (PCC) is used as an
antidote to warfarin, replacing coagulation factors II, VII,
IX, and X in their zymogen or inactive forms. Haemo-
philiacs with inhibitors are treated with recombinant ac-
tivated factor VII (rFVIIa) and/or activated PCC (aPCC)
containing coagulation factors II, IX, and X, and FVIIa.
Several studies have evaluated the reversing effect of
these surrogate antidotes on haemostatic parameters in
animals [12, 13] and by using blood from healthy sub-
jects taking rivaroxaban or blood spiked with rivaroxa-
ban ex vivo [14–20]. It has been shown that different
PCCs incompletely reverse the anticoagulation effect of
rivaroxaban on the thrombin generation assay (TGA)
parameter endogenous thrombin potential (ETP) [21],
and there is increasing evidence suggesting that aPCC
and rFVIIa have a better effect [14, 17, 19]. To our
knowledge, the reversing effect of those agents has not
yet been studied on patients taking rivaroxaban for
therapeutic reasons.
The aims of the present study were to compare PCC,
aPCC and rFVIIa as surrogate antidotes in 50 patients
on therapeutic rivaroxaban doses, and to find the most
effective dose to reverse the anticoagulant effect of rivar-
oxaban in these patients.
Methods
Study design
This is an in vitro study where the ability of PCC, aPCC
and rFVIIa to reverse the effect of rivaroxaban was
tested in blood collected from patients treated with
rivaroxaban.
Participants
Fifty patients treated with therapeutic doses of rivaroxa-
ban for various approved indications and 40 healthy
controls, without previous history of vascular disease,
were recruited in the study. Patients between 18 and
85 years of age who had taken rivaroxaban for more
than two months were eligible. Controls were recruited
from the same age group. Ongoing treatment with anti-
platelet drug(s) and/or non-steroidal antiinflammatory
drug(s) was an exclusion criterium for both patients and
controls. All participants gave written informed consent,
and the study was approved by the Norwegian regional
committee for medical and health research ethics.
Haemostatic agents and doses
We evaluated the following reversal agents in this study:
4-PCC (Cofact®, Sanquin, Amsterdam, the Netherlands),
aPCC (FEIBA®, Baxter AG, Vienna, Austria) and rFVIIa
(Novoseven®, NovoNordisk, Copenhagen, Denmark).
The concentrations included in this study were chosen
to imitate 80%, 100% and 125% of the doses suggested
for clinical use in case of a major bleeding in a patient
treated with a DOAC according to existing guidelines.
For PCC the suggested 100% dose is 40 IU/kg, aPCC
50 IU/kg and rFVIIa 90 μg/kg [22]. The drugs were dis-
solved in sterile water to stock solutions of 34 IU/mL
PCC, 34 IU/mL aPCC and 68 μg/mL rFVIIa. Doses of
the spiked haemostatic agents were calculated assuming
that an adult had 65 mL blood/kg.
Blood collection
Blood was collected from an antecubital vein of the pa-
tients through a 21Gx19 mm butterfly needle (Vacuette®
Greiner Bio-One GmbH, Kremsmunster, Austria) with
minimal use of stasis. The first 2-4 mL of blood was dis-
carded. The blood collection tubes for the measure-
ments of thrombin generation and thromboelastometry
(0,109 M citrate Monovette®, Sarstedt, Nümbrecht,
Germany) were manually prefilled with Corn Trypsin
Inhibitor (CTI) (Haematologic Tecnologies Incorporates,
Essex Junction, VT, USA) at a final concentration of
20 μg/mL. Test tubes that were not filled completely
were discarded. For anti-FXa activity measurements we
used 4.5 mL Vacutainer® tubes (Becton-Dickinson,
Franklin Lakes, NJ, USA) containing 0.5 mL 0.109 M
buffered citrate without CTI. The blood sampling was
performed at the time of presumed peak concentration
of rivaroxaban in the patients, about 2 h after the drug
intake.
Preparations
For measurements of rivaroxaban concentration by an
anti-FXa activity assay, citrated plasma was obtained
after centrifugation for 15 min at 2000 g in RT. The
supernatant was carefully collected and stored at -80 °C
for 2–3 months before measurements of anti-FXa activ-
ity were performed.
Whole blood containing CTI for measurements of
thromboelastometry and thrombin generation from each
patient was pooled and divided into 10 aliquots of 5 mL.
Haemostatic agents were added in the doses mentioned
above, and one aliquot was always left untreated to rep-
resent the baseline value.
Aliquots of whole blood spiked with three different
haemostatic agents at increasing concentrations and the
untreated aliquot were incubated at 37 °C for 30 min.
Then the samples were further subdivided. Platelet-poor
plasma (PPP) was obtained by centrifugation for 13 min
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at 12000 g in RT, and the supernatant was carefully col-
lected. PPP was immediately frozen and stored at -80 °C
for 1–3 months before measurement of thrombin gener-
ation. The remaining whole blood was incubated at 37 °C
for another 30–90 min before measurements by throm-
boelastometry were performed.
Anti-FXa activity measurements
To measure rivaroxaban concentration in citrated plasma,
an anti-FXa activity method calibrated for rivaroxaban
was performed on STA-R Evolution® coagulometer
(Diagnostica Stago S.A.S., Asnières sur Seine, France) [23]
according to the manufacturer’s instructions.
Thrombin generation assay
Thrombin generation was measured in PPP using the
Calibrated Automated Thrombogram (CAT) (Diagnostica
Stago, Asnière, France) with the Thrombinoscope software
(Thrombinoscope BV®, Maastricht, The Netherlands)
[24, 25]. PPP, supplemented with the three different
reversal agents in three different concentrations, were
run in triplicates. The thrombin generation parame-
ters lag time, peak of maximum thrombin concentra-
tion, velocity index and the total amount of thrombin
generated, i.e. endogenous thrombin potential (ETP),
were recorded. The PPP reagent containing 5 pM TF
and 4 μM phospholipids was used to initiate throm-
bin generation.
Thromboelastometry
CTI-containing whole blood (with reversal agents in
three different concentrations) were run in duplicates
and the clotting time (CT; seconds), clot formation time
(CFT; seconds), maximum velocity (MaxV; mm/s), area
under curve (AUC) and maximum clot firmness (MCF;
mm) were measured by ROTEM® (TEM Innovations,
Munich, Germany) with low tissue factor activated
ROTEM [26]. Prior to measurements, the plastic test
cups were prepared with 40 μL buffer (a mixture of
equal parts of buffer 1: 20 mM Hepes, 150 mM NaCl,
pH 7.4 and buffer 2: 20 mM Hepes, 150 mM NaCl,
200 mM CaCl2, pH 7.4). Recombinant relipidated TF
(Innovin®, Dade Behring, Liederbach, Germany) diluted
in a total volume of 20 μL of buffer 1 was also added.
To initiate the reaction, whole blood (280 μL) was
added and the total volume of reagents and whole
blood in each cup was 340 μL. The final TF dilution
was 1:70 000, corresponding to a theoretical concen-
tration of 0.35 pM.
Statistical analysis
The analysis of variance (ANOVA-test) was used
followed by the post-hoc test Tukey multiple compari-
son. Statistical calculations were performed by using
SPSS version 21 (SPSS, Inc, Chicago, USA) and statis-
tical significance was set to p < 0.05.
The Spearman’s rank correlation coefficient was used
when assessing the relationship between rivaroxaban
concentration and coagulation parameters. The data are
expressed as mean value with a 95% confidence interval
(CI 95%) or one standard deviation (SD).
Results
Between October 2014 and May 2015, 50 patients
treated with therapeutic doses of rivaroxaban were en-
rolled in the study at Akershus University Hospital. In
the same time period 40 controls were included. All 50
patients used 20 mg of rivaroxaban once daily. The indi-
cations for rivaroxaban treatment were deep vein throm-
bosis, pulmonary embolism and atrial fibrillation. The
main characteristics of patients and controls are dis-
played in Table 1.
Anti-FXa activity measurements
The mean rivaroxaban concentration in the patient
group was 216.7 ng/mL (95% CI 188.2–245.3). Rivaroxa-
ban concentrations were compared to thromboelastome-
try parameters in whole blood and to TGA parameters
in PPP. Only data for CT and ETP are shown. The
Spearman’s correlation coefficient between rivaroxaban
concentration and CT was 0,68 (p < 0.005) (Fig. 1a).
There was also a linear negative correlation between riv-
aroxaban levels and ETP in PPP (r = −0.72; p < 0.005)
(Fig. 1b).
Thrombin generation
Rivaroxaban affected all thrombin generation parameters
in PPP. Mean lag time was prolonged more than 3-fold
relative to untreated controls (mean difference 6.5 min,
95% CI 5.7–7.3). Peak concentration was reduced by
almost 90% (mean difference 167.1 nM, 95% CI





Age – years 53.1 (14.9) 50.3 (12.8)
Weight – kg 87.1 (16.5) -
Time after intake – minutes 130.1 (14.9) -
Platelet count – x 109/L 142.6 (54.7) 171.8 (54.3)
Platelet count in PRP – x 109/L 146.3 (44.5) 152.4 (26.0)
Rivaroxaban dose (mg od) 20 0
Sex (female) 26 (52%) 24 (60%)
Deep vein thrombosis 21 (42%) -
Pulmonary embolism 28 (56%) -
Atrial fibrillation 1 (2%) -
Values are given in mean (SD) or n (%)
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161.6–172.7), Velocity Index (VI) by approximately
97% (mean difference 58.2 nM/min, 95% CI 57.8–
58.6) and ETP by approximately 40% (mean difference
532.9 nM*min, 95% CI 416.0–649.8) (Fig. 2).
The haemostatic agents improved the thrombin gener-
ation parameters at varying degrees. PCC in a 100% dose
did not cause a significant shortening of the lag time
(mean difference 1.6 min, 95% CI 1.1–2.2). rFVIIa in
100% dose (90 μg/kg) was more effective than PCC in
shortening the lag time (mean difference 6.6 min, 95%
CI 5.7–7.4) but this effect was not significantly different
from aPCC 100% dose which shortened lag time by 50%
(mean reduction 5.5 min, 95% CI 4.7–6.3) (Fig. 3a). PCC
in a 100% dose almost doubled peak concentration
(mean difference 37.7 nM, 95% CI 29.5–45.9), and so
did the 100% dose of rFVIIa (mean difference 36.1 nM,
95% CI 30.2–42.0). However, both those agents were less
effective than aPCC 100% which caused an increase in
peak concentration by 400% (mean difference 83.9 nM,
95% CI 71.4–96.4) (Fig. 3b). The velocity index (VI)
was increased by 240% by PCC 100% (mean difference
3.0 nM/min, 95% CI 2.3–3.8), and by 400% by rFVIIa
100% (mean difference 6.2 nM/min, 95% CI 4.6–7.9).
aPCC in the 100% dose had a significantly better reversal
effect increasing VI than PCC and rFVIIa and increased
VI by 800% (mean difference 12.9 nM/min, 95% CI 9.6–
14.6) (Fig. 3c). The total amount of thrombin generated,
ETP, was increased by the 100% dose of PCC by 130%
(mean difference 802.5 nM*min, 95% CI 649.2–955.8),
and by the 100% dose of rFVIIa by 80% (mean difference
452.7 nM*min, 95% CI 365.7–539.7). The 100% dose
of aPCC had a more pronounced effect than PCC
and rFVIIa and increased ETP by 235% (mean difference
1382.5 nM*min, 95% CI 1203.1–1561.9) (Fig. 3d).
There was not a dose–response relationship for any of
the reversal agents on any of the TGA parameters. aPCC
125% of the suggested dose in clinical use reversed the
TGA parameters in a similar manner to the 80% dose
aPCC (lag time: p = 0.99, peak concentration: p = 1.0,
velocity index: p = 0.99, ETP: p = 0.6). Furthermore the
reversing effect of the lowest dose aPCC (80%) was more
pronounced than the highest dose of PCC (125%) in all
TGA parameters (p < 0.005) (Fig. 3a-d).
Thromboelastometry
Compared to controls, rivaroxaban doubled the CT
(mean difference 674.4 s, 95% CI 527.8–820.9) (Table 2).
PCC shortened the rivaroxaban-induced prolongation of
CT by 25% (mean difference 386.9 s, 95% CI 263.0–
510.8) and there was not a significant difference between
the 80%, 100% and 125% doses (32 IU/kg, 40 IU/kg or
50 IU/kg). Adding rFVIIa caused a shortening of the CT
by approximately 40% (mean difference 636.6 s, 95% CI
523.4–747.7) and aPCC shortened CT by 60% (mean dif-
ference 892.1 s, 95% CI 762.2–1022.1). There was not a
significant difference between rFVIIa and aPCC in a 100%
Fig. 1 Correlation between rivaroxaban concentration and clotting
time and ETP. a. Correlation between rivaroxaban concentration and
thromboelastometry clotting time (CT) in whole blood. R = 0.68,
p < 0.005, n = 50. b. Correlation between rivaroxaban concentration
and endogenous thrombin potential (ETP) in platelet-poor plasma.
R = −0.72, p < 0.005, n = 47
Fig. 2 Reversal of the rivaroxaban effect by reversal agents shown in
representative thrombograms. Thrombin generation was obtained
by Calibrated Automated Thrombogram (CAT) on platelet-poor
plasma. Thrombograms of the controls and patient samples of
rivaroxaban-treated patients with and without reversal agents added.
The reversal agents shown are prothrombin complex concentrate
(PCC), activated PCC (aPCC) and recombinant factor VIIa (rFVIIa) in
100% dose
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dose nor between the highest doses of these haemostatic
agents. However, aPCC was the only haemostatic agent
that shortened CT down below the level of the controls,
and the 80% dose of aPCC was more effective than the
highest dose (125%) of PCC (p < 0.005) (Fig. 4a)th=tlb=
Treatment with rivaroxaban (Table 2) and addition of
haemostatic agents (data not shown) influenced CFT in
the same manner as CT. However, neither rivaroxaban
(Table 2) nor the haemostatic agents (data not shown)
affected the thromboelastometry parameters MCF, maxV
and AUC.
Subgroup analysis - patients with a high rivaroxaban
concentration
A subgroup analysis was performed on the patients with
the highest rivaroxaban concentrations, defined by a
rivaroxaban concentration >300 ng/L (mean 400.6 ng/mL,
95% CI 335.3–466.0) (n = 6). Those patients had the lon-
gest CT in WB (mean clotting time 2425.6 s, 95% CI
1774.8–3076.3) and lowest ETP in PPP (mean ETP
531.1 nM/min, 95% CI-187.7–1249.9). We found the
same pattern as in the main analysis, i.e. that aPCC
increased ETP more than PCC (p < 0.001) and rFVIIa
(p < 0.001). All three haemostatic agents reduced the
CT in the subgroup analysis, but there was not a sig-
nificant difference between the three drugs (p = 1.0)
(Fig. 4b).
Discussion
In the present study we evaluated the ability of three dif-
ferent non-specific reversal agents, PCC, aPCC, and
rFVIIa, to reverse the anticoagulant effect of rivaroxa-
ban. The TGA and thromboelastometry parameters af-
fected by rivaroxaban were improved by all three
haemostatic agents, but at various degrees. In summary,
aPCC reversed rivaroxaban-induced changes in TGA
(velocity index, peak height and ETP) more efficiently
than PCC and rFVIIa. Also, the rivaroxaban-induced
prolongation of CT in whole blood was shortened more
efficiently by aPCC and rFVIIa than PCC. Adding aPCC
even brought the CT to below the level of the controls,
and also increased the ETP to above the control level.
Furthermore, we did not find an additional effect by in-
creasing the dose of aPCC from 80% to 125% in the
Fig. 3 Difference in thrombin generation parameters after adding reversal agents in different doses. Differences in thrombin generation
parameters are expressed as per cent difference from baseline (rivaroxaban with no haemostatic agent added). The doses of the haemostatic
agents are 80%, 100% and 125% of the suggested doses, as described under study design. a. Lag time obtained by Calibrated Automated
Thrombogram (CAT) on platelet-poor plasma (minutes); b. Peak height of thrombin obtained by CAT on platelet-poor plasma (nM); c. Velocity
index obtained by CAT on platelet-poor plasma (nM/min); d. Endogenous Thrombin Potential (ETP) obtained by CAT on platelet-poor plasma
(nM*min). Control level, the difference between the mean control value and the patient baseline values, is illustrated by the dotted line. *p < 0.005.
PCC: prothrombin complex concentrate, aPCC: activated PCC, rFVIIa: recombinant factor VIIa
Table 2 Thromboelastometry results before adding haemostatic
agents
Patients Controls p-value
Clotting time (CT) - sec 1379.4 (510.2) 705.8 (198.1) <0.001
Clot formation time – sec 278.6 (157.0) 187.6 (40.1) <0.001
Maximum clot firmness – mm 57.4 (9.7) 56.0 (5.2) 0.12
Maximum velocity – mm/s 7.0 (5.5-9.0)a 8.0 (7.0-10.0)a 0.83
Area under the curve –mm x sec 5695.3 (1103.5) 5620.4 (498.1) 0.11
Numbers are given as mean (SD) if not otherwise specified
aMedian (interquartile range)
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assays used in this study. Our finding, i.e. that aPCC was
the most effective drug, is in accordance with previous
studies performed on healthy volunteers [14, 17, 19].
In this study we used the 4-factor PCC, Cofact®, which
does not contain any heparin. However, to exert an anti-
thrombotic effect, protein C and S are present in
Cofact®, but this is not the case for aPCC or rFVIIa
which are pure factor concentrates. How protein C and
S influence the results is not known, and it is possible
that their presence is the reason for the inferior effect of
PCC to reverse the anticoagulant effect of rivaroxaban in
this study. One possible way to find this out would
be to use a 4-factor PCC which does not contain any
natural anticoagulants, for example PPSB-S.D (Solvent
Detergent)®(CAF-DCF, Belgium). The effect of fresh
frozen plasma (FFP) has not been investigated in this
study. FFP is derived from whole blood and contains
all components of the coagulation cascade in physio-
logic concentrations, mostly in inactive forms, and is
traditionally used to reverse the effect of Warfarin.
Because rivaroxaban specifically inhibits FXa, re-
placing all factors in an inactive form is not consid-
ered as an effective treatment of a major bleeding.
The fact that PCC is widely used as a reversal agent in
rivaroxaban-treated patients is partly based on findings
in the study performed by Eerenberg et al. [16] where
the effect of PCC as an effective reversal agent was dem-
onstrated. In another study, Zhou et al. [13] found that
PCC 50 IU/kg had effect impairing increase of cererebral
haematoma induced by rivaroxaban in mice. In these
studies, aPCC was not evaluated and thereafter, several
studies have shown that PCC has an insufficient effect in
reversing the coagulation parameters (ETP and pro-
thrombin time in PPP) altered by rivaroxaban [21]. Fur-
thermore, Escolar et al. and Perzborn et al. have shown
that aPCC and rFVIIa had a superior effect compared to
PCC in shortening the CT in whole blood (thromboelas-
tometry) and aPCC had a better effect in improving
TGA parameters in rivaroxaban-spiked samples [17, 19].
Our results were also partly in line with a study per-
formed by Herrmann and collegues where 15 patients
treated prohylactically with a low dose of rivaroxaban
before orthopaedic surgery were included [27]. Here
PCC and aPCC proved to be more effective reversal
agents than rFVIIa, but, in contrast to our study rivarox-
aban did not affect the thromboelastometry parameters
CT and CFT. However, Herrmann and coauthors in-
cluded patients with lower doses of rivaroxaban and a
lower mean concentrations of rivaroxaban may therefore
be a reasonable explanation for this difference. Another
possible explanation may be different sampling condi-
tions of whole blood (without CTI) and the use of differ-
ent initiating reagents.
In our study, there was not a significant difference in
efficacy between the different doses of aPCC. One ex-
planation for the lack of dose-dependency might be that
the amount of TF used to initiate the thrombin gener-
ation was too high to detect minor dose–response rela-
tionships for the reversal agents. Another reason for the
lack of dose–response relationship may be that the
maximum effect has already been reached at a dose of
80% aPCC. Whether this is the case in vivo, is not
known. We did not test higher doses because this infor-
mation in clinical practice is not considered useful. To
test lower doses, however, could have given us interest-
ing information.
There are concerns about the thrombogenicity of the
haemostatic agents we have studied [28–30] and clinical
data about thromboembolic complications associated
with reversal of DOACs are limited. Cases have been re-
ported where aPCC has been administrated to patients
Fig. 4 Differences in clotting time in whole blood (thromboelastometry)
after adding haemostatic agents in different concentrations. Differences
in clotting time expressed as per cent reduction from baseline
(rivaroxaban with no haemostatic agent added). The doses of the
haemostatic agents are 80%, 100% and 125% of the suggested
doses, as described under study design. Control level, the
difference between the mean control value and the patient
baseline values, is illustrated by the dotted line. a. Rivaroxaban-
treated patients, the whole group, n = 50. b. Subgroup with the
highest rivaroxabanconcentrations (>300 ng/L), n = 6. *p < 0.005.
PCC: prothrombin complex concentrate, aPCC: activated prothrombin
complex concentrate, rFVIIa: recombinant Factor VIIa
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under DOAC treatment with an intracranial bleeding,
and an increased risk of thrombosis was not observed
[31–34]. One of the questions we asked in our study was
whether a lower dose of a haemostatic agent than the
guidelines recommend would be sufficient to reverse the
anticoagulation effect of rivaroxaban. Because the lowest
dose of aPCC (80%) was significantly more effective in
reversing rivaroxaban-induced alterations in the coagula-
tion assays than the highest doses PCC and rFVIIa, and
because aPCC reversed ETP and CT to beyond the
levels of the controls, one might speculate that even a
lower dose of aPCC than 80% could be sufficient for re-
versing the rivaroxaban-induced changes. A lower dose
might also reduce the risk of thromboembolic events.
Different doses of rivaroxaban to imitate an overdose
situation were not included in this study. We did, how-
ever, a subgroup analysis (n = 6) of the patients with the
highest rivaroxaban concentrations (>300 ng/mL). Those
six patients also had the longest clotting time in whole
blood. and the lowest ETP in PPP. Like in the main pa-
tient group we found that the reversing effect of aPCC
was superior to the other reversal agents measured by
ETP in PPP but we did not see a difference between the
reversal agents in shortening of the CT. However, the
lack of statistical difference of the post-hoc test might be
due to the low number of cases in the subgroup.
A limitation of our study is that it was an in vitro
study and will therefore not completely reflect the in
vivo situation. In contrast to previous studies, we re-
cruited patients taking rivaroxaban for therapeutic rea-
sons which may have given us results closer to a real life
situation. A positive impact of aPCC on the clinical out-
come of an actively bleeding patient receiving rivaroxa-
ban has been reported in several cases. This is, however,
not studied in clinical trials [31–34]. It is also a general
issue whether coagulation assays are predictive to assess
the risk of bleeding. Only randomized clinical trials may
be able to give such information.
Conclusions
The haemostatic agent aPCC reversed rivaroxaban-
induced changes in TGA parameters more efficiently
than PCC and rFVIIa, and thromboelastometry parame-
ters more efficiently than PCC in vitro. We studied three
different concentrations of PCC, aPCC and rFVIIa and
did not find a dose–response relationship in any of these
drugs. Given the potential prothrombotic effect of these
drugs, doses beyond suggestions in guidelines should be
avoided.
We found a strong correlation between ETP and CT
and the rivaroxaban concentration. However, future
studies are needed to evaluate if these parameters can be
used to identify a clinically relevant hypocoagulability or
non-compliance in rivaroxaban-treated patients.
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